New discovery of scientists about lung cancer
Amgen announced that their new drug called LumKras has reduced the risk of disease progression in lung cancer patients by 34%.
This drug, which was able to get FDA approval last year through an accelerated process, was introduced as an alternative to chemotherapy, but it was carried out during research and the results of it included bad liver effects.
Also, the results of tests and studies of this drug on 345 lung cancer patients are supposed to be presented at the EMSO 2022 seminar, which will be held on September 9-13 in Paris.
Amgen , Lung , Cancer , Emso , FDA , Paris٫lumkras